Navenibart (STAR-0215) Astria initiated the ALPHA-ORBIT pivotal Phase 3 trial of navenibart in people with hereditary angioedema (HAE) in February 2025, with top-line results expected in early 2027.

Astria Therapeutics, Inc.’s ATXS share price has surged by 11.17%, which has investors questioning if this is right time to ...

Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310.

Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...

Equities research analysts at Wedbush cut their Q1 2025 earnings estimates for Astria Therapeutics in a note issued to investors on Wednesday, March 12th. Wedbush analyst L. Chico now anticipates that ...

Astria Therapeutics has commenced the randomised, placebo-controlled ALPHA-ORBIT Phase III trial of navenibart to treat individuals with hereditary angioedema (HAE). The global, double-blind trial ...

Wedbush analyst Laura Chico maintained a Buy rating on Astria Therapeutics (ATXS – Research Report) today and set a price target of $28.00. The ...

Atopic dermatitis (AD) is a chronic, inflammatory skin condition driven by complex immune mechanisms involving T cells. In the context of AD, OX40, a costimulatory receptor present on activated T ...

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D ...